PURPOSE: Pigment epithelial-derived factor (PEDF) is a potent angiogenesis inhibitor with multiple other functions, some of which enhance tumor growth. Our previous studies mapped PEDF antiangiogenic and prosurvival activities to distinct epitopes. This study was aimed to determine the minimal fragment of PEDF, which maintains antiangiogenic and antitumor efficacy. EXPERIMENTAL DESIGN: We analyzed antigenicity, hydrophilicity, and charge distribution of the angioinhibitory epitope (the 34-mer) and designed three peptides covering its COOH terminus, P14, P18, and P23. We analyzed their ability to block endothelial cell chemotaxis and induce apoptosis in vitro and their antiangiogenic activity in vivo. The selected peptide was tested for the antitumor activity against mildly aggressive xenografted prostate carcinoma and highly aggressive renal cell carcinoma. To verify that P18 acts in the same manner as PEDF, we used immunohistochemistry to measure PEDF targets, vascular endothelial growth factor receptor 2, and CD95 ligand expression in P18-treated vasculature. RESULTS: P14 and P18 blocked endothelial cell chemotaxis; P18 and P23 induced apoptosis. P18 showed the highest IC50 and blocked angiogenesis in vivo: P23 was inactive and P14 was proangiogenic. P18 increased the production of CD95 ligand and reduced the expression of vascular endothelial growth factor receptor 2 by the endothelial cells in vivo. In tumor studies, P18 was more effective in blocking the angiogenesis and growth of the prostate cancer than parental 34-mer; in the renal cell carcinoma, P18 strongly decreased angiogenesis and halted the progression of established tumors. CONCLUSIONS: P18 is a novel and potent antiangiogenic biotherapeutic agent that has potential to be developed for the treatment of prostate and renal cancer.
PURPOSE:Pigment epithelial-derived factor (PEDF) is a potent angiogenesis inhibitor with multiple other functions, some of which enhance tumor growth. Our previous studies mapped PEDF antiangiogenic and prosurvival activities to distinct epitopes. This study was aimed to determine the minimal fragment of PEDF, which maintains antiangiogenic and antitumor efficacy. EXPERIMENTAL DESIGN: We analyzed antigenicity, hydrophilicity, and charge distribution of the angioinhibitory epitope (the 34-mer) and designed three peptides covering its COOH terminus, P14, P18, and P23. We analyzed their ability to block endothelial cell chemotaxis and induce apoptosis in vitro and their antiangiogenic activity in vivo. The selected peptide was tested for the antitumor activity against mildly aggressive xenografted prostate carcinoma and highly aggressive renal cell carcinoma. To verify that P18 acts in the same manner as PEDF, we used immunohistochemistry to measure PEDF targets, vascular endothelial growth factor receptor 2, and CD95 ligand expression in P18-treated vasculature. RESULTS:P14 and P18 blocked endothelial cell chemotaxis; P18 and P23 induced apoptosis. P18 showed the highest IC50 and blocked angiogenesis in vivo: P23 was inactive and P14 was proangiogenic. P18 increased the production of CD95 ligand and reduced the expression of vascular endothelial growth factor receptor 2 by the endothelial cells in vivo. In tumor studies, P18 was more effective in blocking the angiogenesis and growth of the prostate cancer than parental 34-mer; in the renal cell carcinoma, P18 strongly decreased angiogenesis and halted the progression of established tumors. CONCLUSIONS:P18 is a novel and potent antiangiogenic biotherapeutic agent that has potential to be developed for the treatment of prostate and renal cancer.
Authors: D J Good; P J Polverini; F Rastinejad; M M Le Beau; R S Lemons; W A Frazier; N P Bouck Journal: Proc Natl Acad Sci U S A Date: 1990-09 Impact factor: 11.205
Authors: Olga V Volpert; Tetiana Zaichuk; Wei Zhou; Frank Reiher; Thomas A Ferguson; P Michael Stuart; Mohammad Amin; Noel P Bouck Journal: Nat Med Date: 2002-04 Impact factor: 53.440
Authors: Marta Garcia; Nuria Isabel Fernandez-Garcia; Veronica Rivas; Marta Carretero; Maria J Escamez; Alicia Gonzalez-Martin; Estela E Medrano; Olga Volpert; Jose L Jorcano; Benilde Jimenez; Fernando Larcher; Marcela Del Rio Journal: Cancer Res Date: 2004-08-15 Impact factor: 12.701
Authors: Tetiana A Zaichuk; Emelyn H Shroff; Rebekah Emmanuel; Stephanie Filleur; Thomas Nelius; Olga V Volpert Journal: J Exp Med Date: 2004-06-07 Impact factor: 14.307
Authors: Elena V Rosca; Jacob E Koskimaki; Niranjan B Pandey; Amir P Tamiz; Aleksander S Popel Journal: Chem Biol Drug Des Date: 2012-04-27 Impact factor: 2.817
Authors: Jose L Orgaz; Alberto Benguria; Cristina Sanchez-Martinez; Omar Ladhani; Olga V Volpert; Benilde Jimenez Journal: Melanoma Res Date: 2011-08 Impact factor: 3.599
Authors: Daniel P Fitzgerald; Preeti Subramanian; Monika Deshpande; Christian Graves; Ira Gordon; Yongzhen Qian; Yeva Snitkovsky; David J Liewehr; Seth M Steinberg; José D Paltán-Ortiz; Mary M Herman; Kevin Camphausen; Diane Palmieri; S Patricia Becerra; Patricia S Steeg Journal: Cancer Res Date: 2012-01-01 Impact factor: 12.701
Authors: Nader Sheibani; Ismail S Zaitoun; Shoujian Wang; Soesiawati R Darjatmoko; Andrew Suscha; Yong-Seok Song; Christine M Sorenson; Victor Shifrin; Daniel M Albert; Ignacio Melgar-Asensio; Irawati Kandela; Jack Henkin Journal: Exp Eye Res Date: 2020-04-06 Impact factor: 3.467
Authors: Alexandre Chlenski; Lisa J Guerrero; Radhika Peddinti; Jared A Spitz; Payton T Leonhardt; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn Journal: Mol Cancer Date: 2010-06-04 Impact factor: 27.401